This sector-wide optimism arrived at a complex moment for the company. BioNTech is in the midst of a strategic transition, shifting its focus from pandemic-era vaccine manufacturing toward oncology. This pivot has been complicated by recent clinical setbacks and organizational restructuring. On August 28, the company announced the cancellation of a Phase 2 clinical trial for its personalized mRNA cancer vaccine, BNT122-01, intended for colorectal cancer. The therapy did not demonstrate statistically significant efficacy, though no safety concerns were reported. Consequently, BioNTech lowered its full-year revenue guidance to €1.6 billion–€1.9 billion, down from a previous forecast of €2 billion–€2.3 billion.
The market reaction to these developments has been mixed. BMO Capital Markets downgraded BioNTech from “outperform” to “market perform” on September 8, citing waning global demand for COVID-19 vaccines and the pipeline setback. The firm also reduced its 12-month price target from $128 to $105. Other analysts have trimmed their estimates in response to the discontinuation of specific projects, including the FixVac melanoma and iNeST adjuvant colorectal cancer programs. Bank of America lowered its price target to $114 from $122, while maintaining a buy recommendation, and Morgan Stanley adjusted its target slightly downward to $114 while keeping an Overweight rating.
Amidst this shifting landscape, BioNTech CEO Ugur Sahin has continued to sell shares. A filing with the US Securities and Exchange Commission reveals that Sahin sold 36,209 ordinary shares at $95.3733 per share on Friday, and 27,000 shares at $92.3142 per share on Thursday. These transactions were executed under a Rule 10b5-1 trading plan established on June 3, 2026. Such automated plans are standard practice for US-listed executives to avoid insider trading concerns, though they are closely monitored during periods of corporate repositioning. As of October 8, 2026, Sahin’s holding company, Medine GmbH, retained 39,218,111 BioNTech ordinary shares.
Investors remain divided on the company’s valuation. While the stock has rebounded over the past year, it has still declined 67.2% over the last five years. BioNTech currently trades at a price-to-sales (P/S) ratio of 9.5x, which is below the biotech industry average of 13.1x and the peer group average of 10.2x. However, valuation models suggest the stock is priced at a premium relative to its adjusted fundamentals, with a “Fair Ratio” model indicating a more grounded P/S of 6.2x. The company’s strong balance sheet provides a cushion, with cash, cash equivalents, and security investments totaling roughly €16.6 billion (approximately $19 billion) as of June 30, 2026. Its market capitalization hovers around $24 billion, or approximately EUR 20.99 billion.
BioNTech is also streamlining its operations to align with its oncology focus. The company confirmed it will wind down its German sites in Tübingen, Marburg, and Idar-Oberstein in stages after failing to find buyers, a move that could affect as many as 1,860 jobs. Despite these cuts and recent trial cancellations, the company maintains a robust pipeline with over 25 Phase 2 and Phase 3 clinical studies underway. Recent data showed that gotistobart nearly doubled median overall survival in previously treated patients with squamous non-small cell lung cancer. BioNTech expects to report data from 11 other late-stage studies by the end of 2029, covering breast, gastrointestinal, and lung cancers.
The immediate outlook hinges on whether the NIH initiative and the remaining clinical programs can sustain investor confidence. With data from three additional studies expected before the end of the year, the market will be watching closely to see if BioNTech’s oncology pipeline can translate into durable revenue, offsetting the continued erosion of its vaccine business.
